TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04150640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nal-IRI
Description: chemotherapy drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: chemotherapy drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: chemotherapy drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: chemotherapy drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: chemotherapy drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: chemotherapy drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: chemotherapy drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: chemotherapy drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: chemotherapy drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: immunotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: immunotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: immunotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: immunotherapy
Study: NCT00968916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ombrabulin (AVE8062)
Description: Pharmaceutical form: injection solution~Route of administration: intravenous infusion
Study: NCT02336308

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, Normal Saline
Study: NCT03074162

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac Sodium
Description: twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac & Capsaicin
Description: twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac Sodium Topical Gel
Description: twice daily
Study: NCT03973489

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging (MRI)
Description: On visits 2 and 3, subjects will undergo a baseline MRI scan approximately 1 hour after the start of each visit followed by drug administration (placebo or MA) and a second scan 1.5 hours after that.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging (MRI)
Description: On visits 2 and 3, subjects will undergo a baseline MRI scan approximately 1 hour after the start of each visit followed by drug administration (placebo or MA) and a second scan 1.5 hours after that.
Study: NCT01513941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaprevir
Description: Type=exact number, unit=mg, number=750 or 1125, form=tablet, route=oral. the patients will receive 2 oral tablets every 8 hours for 12 weeks except for patients on efavirenz who will receive 1125mg (3 oral tablets) every 8 hours for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Type=exact number, unit=mg, number=400, form=tablet, route=oral. The patients will receive 2 oral ribavirin tablets twice daily for 24 or 48 weeks, based on the response guided therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated-Interferon-alfa-2a
Description: Type=exact number, unit=microgram, number=180, form=injection, route=subcutaneous The patients will receive Peg-IFN-alfa-2a 180 microgram once a week for 24 or 48 weeks; based on the response guided therapy.
Study: NCT02847416

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BreatheMAX breathing device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BreatheMAX breathing device
Study: NCT03350191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR425899
Description: Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR425899
Description: Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga] Ga-DO3A-VS-Cys40-Tuna-2 (glucagon receptor tracer)
Description: Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga] Ga-DO3A-VS-Cys40-Tuna-2 (glucagon receptor tracer)
Description: Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga] Ga-DO3A-VS-Cys40-Exendin-4 (GLP-1 receptor tracer)
Description: Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga] Ga-DO3A-VS-Cys40-Exendin-4 (GLP-1 receptor tracer)
Description: Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous
Study: NCT02308241

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: self-administer ribavirin 1400 mg PO BID (total dose, 2800 mg/day)
Study: NCT00231582

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epirubicin
Description: epirubicin

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: high-dose and autologous stem cell transplantation
Description: high-dose and autologous stem cell transplantation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Description: ifosfamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: carboplatin
Study: NCT02435433

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Administered IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ramucirumab
Description: Administered IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ramucirumab
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Administered IV
Study: NCT04539145

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chocolate PTA Balloon
Description: Chocolate PTA Balloon
Study: NCT02435433

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Administered IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered IV
Study: NCT00964054

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Public Health Dose of Exercise (PHD)
Description: 17.5 kcal per kilogram per week

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low Dose Exercise (LD)
Description: 7.0 kcal per kilogram per week
Study: NCT01219140

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 2 POMx Capsules
Description: 2 POMx Capsules daily

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: 2 placebo Capsules
Description: 2 placebo Capsules daily
Study: NCT03973151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HL-085
Description: HL-085 is one MEK inhibitor.
Study: NCT03594617

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interaction Competencies with Children - for Caregiver
Description: Interaction Competencies with Children - for Caregiver (ICC-C) aims to reduce maltreatment and to improve care quality in institutional care facilities. Following the idea of a train-the-trainer approach, ICC-C is designed to be delivered by trained local facilitators. ICC-C is based on attachment, behavioral and social learning theories.~The key principles are its feasibility in low-resource contexts, participatory approach, and practical orientation. ICC-C includes sessions on (a) caregiver-child interaction, (b) maltreatment prevention, (c) effective non-violent caregiving strategies, and (d) identifying and supporting burdened children.
Study: NCT03530241

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Presence of bile duct stones
Description: MRCP verified gall stones in the bile ducts

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Non-presence of bile duct stones
Description: MRCP without bile duct stones
Study: NCT02946255

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Welcome Basket (WB)
Description: Peer Support Workers (PSWs) hold 1-2 meetings with clients (30-60 minutes) in the 2-week period before they are discharged from hospital. They describe the program and undertake an assessment. From this assessment the two core components of the intervention are initiated. First, a welcome basket is created for the client. The PSW also forms a plan with the client about tours of their neighbourhood to familiarize them with the local resources and support them in building confidence in accessing their local communities. These activities will take place through weekly visits (2 hours/visit) in the 4 weeks immediately following discharge. WB will be provided in combination with core Cognitive Adaptation Training (CAT) compensatory interventions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Welcome Basket Brief (WBbr)
Description: The brief version of the Welcome Basket (WBbr) was developed based upon the observation in feasibility testing that for some participants much of the benefit of this approach appeared to be centred upon the visits immediately prior and subsequent to discharge. In the WBbr the same core components will be present, albeit in an abbreviated form with one 30-60 minute visit in the week prior to discharge and a single, 3-hour visit in the week subsequent to discharge in which the welcome basket would be delivered, core CAT strategies discussed and implemented, and some basic orientation to community resources undertaken. This brief version of the intervention has not to date been studied.
Study: NCT03973489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methamphetamine Hydrochloride Tablets
Description: Study participants will receive an oral dose of methamphetamine hydrochloride on one of two scan days and an identical looking placebo in tablet form on the other scan day. Drug type will be randomized between the two visits. Participants will receive the following doses of methamphetamine hydrochloride in accordance with their weight: if weight is between 50-60 kg, 15 mg dose of methamphetamine hydrochloride will be administered. Similarly, for 60-80 kg, 20 mg dose; 80-100 kg, 25 mg dose; and 100+ kg, 30 mg dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methamphetamine Hydrochloride Tablets
Description: Study participants will receive an oral dose of methamphetamine hydrochloride on one of two scan days and an identical looking placebo in tablet form on the other scan day. Drug type will be randomized between the two visits. Participants will receive the following doses of methamphetamine hydrochloride in accordance with their weight: if weight is between 50-60 kg, 15 mg dose of methamphetamine hydrochloride will be administered. Similarly, for 60-80 kg, 20 mg dose; 80-100 kg, 25 mg dose; and 100+ kg, 30 mg dose.
Study: NCT04539145

Intervention type: DEVICE
Group type: OTHER
Intervention: conventional balloon angioplasty
Description: conventional bal-loon angioplasty
Study: NCT04028245

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spartalizumab
Description: Spartalizumab at 400 mg weeks x 2 doses prior to radical nephrectomy Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab
Description: Canakinumab 300 mg IV Q4 weeks x 2 doses prior to radical nephrectomy Infusion
Study: NCT02872571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intramuscular Islet Autograft
Description: Intramuscular Islet Autograft After Extensive Pancreatectomy
Study: NCT01900639

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: change time of intake of aspirin

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: change time of intake of aspirin
Study: NCT00156702

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Feedback and Motivational Interviewing

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smoking Prevention Video
Study: NCT03348384

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [C-11]
Description: Radiolabel

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [C-11]
Description: Radiolabel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOP-1A
Description: Tracer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOP-1A
Description: Tracer
Study: NCT03469388

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pulse wave analyses; central blood presaure parameters
Description: Pulse wave analyses; central blood presaure parameters
Study: NCT03010761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: escitalopram
Description: antidepressant use for the betel-quid abstinence

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moclobemide
Description: antidepressant use for the betel-quid abstinence

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo - Cap
Description: Placebo - Cap
Study: NCT01165580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: valganciclovir [Valcyte]
Description: oral dose, Days 1 and 2
Study: NCT03504670

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early Amniotomy
Description: This intervention involves using an amniotomy hook to rupture the membranes during a sterile vaginal exam. This intervention will be performed prior to the cervix being dilated 4cm.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Late Amniotomy
Description: This intervention involves using an amniotomy hook to rupture the membranes during a sterile vaginal exam. This intervention will be performed once the cervix is at least 4cm dilated.
Study: NCT01863810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KW21052
Description: 1 Tablet contains 300mg of pregabalin. Oral, once a day, for 8 weeks.
Study: NCT01863810

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lyrica
Description: 1 Capsule contains 150mg of pregabalin. Oral, twice a day, for 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lyrica (low dose)
Description: 1 Capsule contains 75mg of pregabalin. Oral, twice a day, for 1 week.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lyrica (low dose)
Description: 1 Capsule contains 75mg of pregabalin. Oral, twice a day, for 1 week.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo of KW21052
Description: Oral,once a day, for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of Lyrica
Description: Oral, twice a day, for 8 weeks.
Study: NCT02648321

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: Motivational Interviewing is a patient-centered, tailored counselling intervention for exercise, through which patients' motives to change are identified. Personal ideas and ambivalence are explored. The discrepancies between the present behavior and the patient's own future goals are amplified. The patient's intrinsic motivation for change is increased through the process.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education
Description: General education about healthy lifestyle and diet.
Study: NCT01818960

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IRA-PCI
Description: IRA only PCI at the time of Primary PCI

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SS-PCI
Description: Same sitting multivessel PCI as an adjunct to primary PCI
Study: NCT02707809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine infusion
Study: NCT02186366

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Abdominal Massage Therapy
Description: Abdominal Massage Therapy , 30 minutes, three times one week for 6 weeks. If the subjects have recovered in the treatment of 6 weeks, we can end treatment early.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buspirone
Description: Buspirone by mouth 5mg three times per day for 6week. If the subjects have recovered in the treatment of 6 weeks, we can end treatment early.
Study: NCT04167371

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Biofeedback
Description: Three sessions by biofeedback will be performed during the first 3 weeks of the intervention period. In each session patients will be taught to control abdominal and thoracic muscular activity by providing a visual display of the abdominal and thoracic perimeter; patients will be instructed to perform the same exercises before and after breakfast, lunch and dinner during the 4-week intervention period.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Three sessions will be performed during the first 3 weeks of the intervention period. In each session abdominal and thoracic perimeter will be recorded but not shown to the patient; patients will take a pill of placebo containing 0.5 g glucose and no specific instructions will be provided. Patients will be instructed to take a pill of placebo before breakfast, lunch and dinner during the 4-week intervention period.
Study: NCT03280095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: co-codamol 15mg/500mg capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: co-codamol 15mg/500mg capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: co-codamol 30mg/500mg tablet
Study: NCT00908011

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe
Description: 10mg/day ezetimibe in addition to ongoing rosuvastatin treatment (10mg/day)- tablet, orally, 10mg/day for 12 weeks
Study: NCT03555539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danicopan
Description: Oral tablet.
Study: NCT03973489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral tablet
Description: Study participants will receive an oral dose of methamphetamine hydrochloride on one of two scan days and an identical looking placebo in tablet form on the other scan day. Drug type will be randomized between the two visits.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral tablet
Description: Study participants will receive an oral dose of methamphetamine hydrochloride on one of two scan days and an identical looking placebo in tablet form on the other scan day. Drug type will be randomized between the two visits.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral tablet
Description: Study participants will receive an oral dose of methamphetamine hydrochloride on one of two scan days and an identical looking placebo in tablet form on the other scan day. Drug type will be randomized between the two visits.
Study: NCT02433093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basimglurant
Description: Participants will receive once-daily oral basimglurant capsules in a multiple ascending dose regimen. Basimglurant dose will be titrated over 22 days; dose escalations will be separated by at least 4 days, with the final dose administered for a minimum of 14 days. The minimum starting dose will be 1.5 mg, which can be titrated up to a maximum dose of 4.0 mg. Intrapatient dose increments will not exceed 1.0 mg every 4 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basimglurant
Description: Participants will receive once-daily oral basimglurant capsules in a multiple ascending dose regimen. Basimglurant dose will be titrated over 22 days; dose escalations will be separated by at least 4 days, with the final dose administered for a minimum of 14 days. The minimum starting dose will be 1.5 mg, which can be titrated up to a maximum dose of 4.0 mg. Intrapatient dose increments will not exceed 1.0 mg every 4 days.
Study: NCT00733512

Intervention type: DEVICE
Intervention: ReSTOR
Description: Patients were implanted with the AcrySof ReSTOR Aspheric +4 Intraocular Lens (IOL) in one or both eyes for treatment of cataract.
Study: NCT00950690

Intervention type: DRUG
Intervention: Xalatan 0.005% eye drops
Description: ophthalmic solution dosed once daily for 3 months
Study: NCT02752867

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jianpi Yishen Huatan Granules
Description: Jianpi Yishen Huatan Granules contain Herba cistanche，Fructus Alpinia Oxyphyllae，Rhodiola rosea, Polygala tenuifolia willd and Coptis chinensis.Jianpi Yishen Huatan Granules dissolved in water of 100 ml ,po, bid of each 90-days cycle. Number of treatment cycles: one

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: the placebo
Description: Treat with the placebo which contain 5% of prescription of Jian Pi Yi Shen Hua Tan Granules and 95% dextrin.The placebo dissolved in water of 100 ml ,po, bid of each 90-days cycle. Number of cycles: one
Study: NCT03245671

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Kenalog Injectable Product
Description: 80 mg of Kenalog will be used.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Decadron Phosphate, Injectable
Description: 15 mg of Decadron will be used.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural Steroid Injection
Description: Patient will receive epidural steroid injections of either Kenalog or Decadron.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural Steroid Injection
Description: Patient will receive epidural steroid injections of either Kenalog or Decadron.
Study: NCT03623984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gallium Dotatate
Description: Radioguided Surgery for Pancreatic- Neuroendocrine Cancers
Study: NCT03952897

Intervention type: OTHER
Intervention: balneotherapy
Description: 10 days of balneotherapy with immersion techniques using Fitero spa water.
Study: NCT04531319

Intervention type: DIAGNOSTIC_TEST
Intervention: Flow cytometric analysis
Description: Flow cytometric analysis of T helper, T cytotoxic cells, NK cells and monocytes

Intervention type: DIAGNOSTIC_TEST
Intervention: Flow cytometric analysis
Description: Flow cytometric analysis of T helper, T cytotoxic cells, NK cells and monocytes
Study: NCT03554538

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web app exercises program
Description: Exercise on an evidence based program for shoulder pain with web app animations to improve performance and adherence

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise program
Description: Exercise on an evidence based program for shoulder pain
Study: NCT03973489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral tablet
Description: Study participants will receive an oral dose of methamphetamine hydrochloride on one of two scan days and an identical looking placebo in tablet form on the other scan day. Drug type will be randomized between the two visits.
Study: NCT02750813

Intervention type: DEVICE
Group type: OTHER
Intervention: Delefilcon A contact lenses

Intervention type: DEVICE
Group type: OTHER
Intervention: Delefilcon A contact lenses